Terry-Ann Burrell, the Chief Financial Officer for Beam Therapeutics Inc. (NASDAQ: BEAM), disclosed on January 18 that she had sold 47,195 shares of the company’s stock. It was determined that the stock was sold at an average price of $45.14 per share, which resulted in a total transaction volume of $2,130,382.30. Following the completion of the transaction, the chief financial officer will have a total of 31,277 shares of the company, each of which has an intrinsic value of $1,411,843.78. On the Securities and Exchange Commission’s (SEC) website, you can access the information submitted to the SEC regarding the transaction, which is currently available.
On November 7, Beam Therapeutics (NASDAQ: BEAM) issued a report that included the company’s financial results, and the report was made public. The company announced that its earnings per share (EPS) for the period under review came in at $1.56, which was $0.26 less than the predictions made by industry professionals for the period, which were $1.30. The company’s quarterly revenue was significantly higher than expected, coming in at $15.80 million, despite analysts’ predictions that the company would only bring in $7.15 million in sales for the period. The return on equity for Beam Therapeutics was negative at 38.93%, and the company’s net margin was also negative at 343.05%. Beam Therapeutics saw an increase in revenue for the quarter of 1,875.0% compared to the same period last year. The company incurred a loss equivalent to $0.42 per share in the same period the year before. The projections of seasoned professionals in the business sector indicate that Beam Therapeutics Inc. will finish 2018 with a loss of 4.87 cents per share.
Hedge funds have been making adjustments to their holdings of the stock recently. In the final quarter of 2018, Ronald Blue Trust Inc. brought its total ownership of Beam Therapeutics stock up to a 623.8% stake from the previous quarter’s level. The most recent quarter saw Ronald Blue Trust Inc. acquire an additional 499 shares of the company’s stock, bringing the total number of shares owned in the business to 579, with a value of $28,000. During the third quarter of the fiscal year, Van ECK Associates Corporation invested in the shares of Beam Therapeutics in the amount of $34,000. Beam Therapeutics received an investment of $43,000 in stock from China Universal Asset Management Co. Ltd. during the third quarter of 2018. During the third quarter, Nisa Investment Advisors LLC brought the total amount of Beam Therapeutics stock it owned to 31.0 percent higher than before. Following purchasing 344 additional shares over the preceding three months, Nisa Investment Advisors LLC is now the owner of 1,454 shares in the company. These shares have a value of $64,000, thanks to the fact that they were acquired over the past three months. During the third quarter, Kessler Investment Group LLC made a new investment in the form of $83,000 worth of shares in Beam Therapeutics. To the tune of 76.70% of the company’s shares, hedge funds and other institutional investors are the owners of those shares.
Following a gain of $2.13 since the morning session on Friday, the price of a share of BEAM stock has risen to $44.54 during the noon session. The company’s stock exchanged hands 769,372 times, with an average volume of 856,198 shares traded each time. The moving average for the company over the past 50 days is $43.24, and the moving average over the last 200 days is $49.94. Both the price-to-earnings ratio of the company, which is currently at -9.34, and its beta value are currently at 1.69. The company’s total value, as represented by its market capitalization, is $3.14 billion. Beam Therapeutics Inc. has traded at a range of prices over the past year, with a low of $27.77 and a high of $80.00. During that time, the company’s stock price fluctuated between extremes.
In recent times, a variety of equity research analysts have communicated their thoughts regarding the company that has been the primary focus of their attention. Beam Therapeutics received an “outperform” rating from SVB Leerink in a research report published on November 7, and the price objective that the firm has set for the company has been reduced from $82.00 to $81.00. Both of these changes were made in response to the fact that the price objective had previously been set at $82.00. Credit Suisse Group lowered its price objective for Beam Therapeutics in a research report published on November 8. The report was distributed on Tuesday. The previous price objective of $65.00 has been reduced to $53.00 and a “neutral.”